Intercept Pharmaceuticals, Inc.
Last week I published an article that looked at the outlook for the top five post-IPO performers of the last year. However, numbers 2-10 are very close in terms of performance, thus I am looking at numbers 6-10 to determine their outlook moving forward.
#10 Intercept Pharmaceuticals (NASDAQ: ICPT)
Intercept has rallied 121.47% since its IPO price, yet has traded with a loss of 3% in 2013. The company more »
Much time has passed since the hey day of the IPO, when they generated tens of millions of dollars almost no matter what the company was. These days dollars are more closely invested in IPO’s and the value of the offered product or service has to show some significant potential worth. Gone are the days when investors would blindly throw money at an IPO. Sometimes they still miss the more »